Single-exciton, biexciton, triexciton, and quadraexciton bands were resolved in the microphotoluminescence spectrum of a single CdTe/CdSe core-shell colloidal quantum dot, revealing nearly blinking-free behavior. Multiexcitons were generated by a sequential filling of electronic shells with the increase of a continuous-wave excitation power, and their probability was evaluated under steady-state conditions. A partial carriers' delocalization was determined at the core-shell interface, and an exciton binding energy was estimated by a second-order perturbation theory.

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevLett.102.197401DOI Listing

Publication Analysis

Top Keywords

spectrum single
8
core-shell colloidal
8
colloidal quantum
8
quantum dot
8
continuous-wave pumping
4
pumping multiexciton
4
multiexciton bands
4
bands photoluminescence
4
photoluminescence spectrum
4
single cdte-cdse
4

Similar Publications

Toward effective oxytocin interventions in autism: Overcoming challenges and harnessing opportunities.

J Psychopharmacol

January 2025

Neuromodulation Laboratory, Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.

Intranasal administration of oxytocin is emerging as a potential pharmacological option for mitigating social difficulties and regulating stress in autism spectrum disorder. However, initial single-dose and multiple-dose trials showed mixed results, with some demonstrating improvements in social and repetitive behavior and others showing no benefit over placebo. This perspective aims to elucidate factors contributing to this variability and to highlight pitfalls and opportunities in the field.

View Article and Find Full Text PDF

Background: A broad-spectrum anti-SARS-CoV-2 monoclonal antibody (mAb), SA55, is highly effective against SARS-CoV-2 variants. This trial aimed at demonstrating the safety, tolerability, local drug retention and neutralizing activity, systemic exposure level, and immunogenicity of the SA55 nasal spray in healthy individuals.

Methods: This phase I, dose-escalation clinical trial combined an open-label design with a randomized, controlled, double-blind design.

View Article and Find Full Text PDF

The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents, particularly infliximab (IFX) and adalimumab (ADA), has significantly expanded the therapeutic arsenal for inflammatory bowel disease (IBD). While these biologics have demonstrated substantial efficacy, they are associated with a spectrum of potential adverse events (AEs). This study aims to evaluate and document these AEs to facilitate optimal patient selection and monitoring strategies of patients undergoing these therapies.

View Article and Find Full Text PDF

Background: In the era of resistance, the design and search for new "small" molecules with a narrow spectrum of activity that target a protein or enzyme specific to a certain bacterium with high selectivity and minimal side effects remains an urgent problem of medicinal chemistry. In this regard, we developed and successfully implemented a strategy for the search for new hybrid molecules, namely, the not broadly known [2-(3-R-1-[1,2,4]-triazol-5-yl)phenyl]amines. They can act as "building blocks" and allow for the introduction of certain structural motifs into the desired final products in order to enhance the antistaphylococcal effect.

View Article and Find Full Text PDF

One of the significant challenges facing modern medicine is the rising rate of antibiotic resistance, which impacts public health, animal health, and environmental preservation. Evaluating antibiotic resistance in wildlife and their environments is crucial, as it offers essential insights into the dynamics of resistance patterns and promotes strategies for monitoring, prevention, and intervention. and genera isolates were recovered from fecal samples of wild animals and environmental samples using media without antibiotic supplementation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!